Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrationsF Formelli, M Clerici, T Campa, et al.European Journal of Neurology|November 27, 2025
Individual Alpha Frequency as an EEG Biomarker of Drug-Related Cognitive Burden in EpilepsyG Assenza, B M Sancetta, G Lippa, et al.European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Long-term tolerability of fenretinide (4-HPR) in breast cancer patientsN Rotmensz, G De Palo, F Formelli, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 6, 2006
Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancerU Veronesi, L Mariani, A Decensi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2007
Plasma testosterone and prognosis of postmenopausal breast cancer patientsAndrea Micheli, Elisabetta Meneghini, Giorgio Secreto, et al.Plos One|March 25, 2022
Recruitment in randomized clinical trials: The MeMeMe experienceIvan Baldassari, Andreina Oliverio, Vittorio Krogh, et al.Tumori|September 1, 1996
Chemoprevention of breast cancer with fenretinide (4-HPR): study of long-term visual and ophthalmologic tolerabilityL Mariani, F Formelli, G De Palo, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 6, 2001
Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancerA Decensi, H Johansson, R Miceli, et al.Tumori|April 4, 1998
Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrualG De Palo, T Camerini, E Marubini, et al.Journal of the National Cancer Institute|November 5, 1999
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancerU Veronesi, G De Palo, E Marubini, et al.Pageof 3